girentuximab

(redirected from WiLex)
Also found in: Acronyms.

girentuximab

A chimeric IgG1 monoclonal antibody that targets carbonic anhydrase IX. Phase-1 and -2 studies of girentuximab plus low-dose IFN-alpha in patients with progressive metastatic renal cell carcinoma indicated that the combination therapy was safe, well tolerated and demonstrated clinical benefit in the patient population.
References in periodicals archive ?
The expected financial impact of this partnership is already reflected in WILEXs financial outlook for the current fiscal year provided in March 2017.
WILEX bought in early 2009 five oncology projects from UCB.
WILEX has completed various clinical studies with the product in different indications, including two Phase II proof of concept trials for pancreatic cancer and metastatic breast cancer.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Wilex AG's corporate website, SEC filings, investor presentations and featured press releases, both from Wilex AG and industry-specific third party sources, put together by Global Markets Direct's team.
Wilex purchased global rights in January 2009 to develop UCB's oncology portfolio including five oncology projects, with UCB keeping exclusive rights to buy back each of these programmes following completion of clinical feasibility studies and take charge of the final development and sale of the products.
Belgian biopharmaceutical company UCB (Euronext:UCB) stated on Thursday that it has increased its shareholding in WILEX AG to approximately 18%, strengthening the strategic alliance between the two firms.
M2 PHARMA-July 10, 2013-UCB obtains rights to antibody programme from Wilex for non-oncology indications(C)2013 M2 COMMUNICATIONS
M2 EQUITYBITES-10 June 2010-UCB increases investment in WILEX to 18%(C)2010 M2 COMMUNICATIONS http://www.
Lohmann is joining MorphoSys after 11 years at Wilex AG where she was most recently senior vice president legal affairs & human resources.
1 February 2012 - German biopharmaceutical company Wilex AG (ETR:WL6) said on Wednesday it had secured gross proceeds of EUR9.
18 January 2012 - German Wilex AG (ETR:WL6) said on Wednesday it had successfully completed a Phase I dose escalation trial with its oral Mitogen activated protein kinase (MEK) inhibitor WX-554 demonstrating activity, safety and tolerance in healthy volunteers.
14 December 2011 - German biopharmaceutical firm WILEX AG (FRA:WL6) and Belgium-based pharma company Ion Beam Applications SA (IBA) (EBR:IBAB) said Wednesday they had agreed with the US Food and Drug Administration (FDA) to discuss with an advisory committee a second study of the drug candidate REDECTANE, targeted at diagnosing, prior to surgery, clear cell Renal Cell Cancer.